CNC-Center for Neuroscience and Cell Biology, CIBB - Centre for Innovative Biomedicine and Biotechnology, University of Coimbra, Coimbra, Portugal.
Santa Casa de São Paulo School of Medical Science, Physiological Sciences, São Paulo, Brazil.
Eur J Clin Invest. 2022 Sep;52(9):e13798. doi: 10.1111/eci.13798. Epub 2022 Apr 30.
Amyotrophic lateral sclerosis (ALS) is a fatal and rapidly progressing neurodegenerative disease that affects motor neurons. This disease is associated with oxidative stress especially in mutant superoxide dismutase 1 (mutSOD1) patients. However, less is known for the most prevalent sporadic ALS form, due to a lack of disease models. Here, we studied oxidative stress profiles in lymphoblasts from ALS patients with mutSOD1 or unknown (undSOD1) mutations.
mutSOD1 and undSOD1 lymphoblasts, as well as sex/age-matched controls (3/group) were obtained from Coriell and divided into 46 years-old-men (C1), 46 years-old-women (C2) or 26/27 years-old-men (C3) cohorts. Growth curves were performed, and several parameters associated with redox homeostasis were evaluated, including SOD activity and expression, general oxidative stress levels, lipid peroxidation, response to oxidative stimulus, glutathione redox cycle, catalase expression, and activity, and Nrf2 transcripts. Pooled (all cohorts) and paired (intra-cohort) statistical analyses were performed, followed by clustering and principal component analyses (PCA).
Although a high heterogeneity among lymphoblast redox profiles was found between cohorts, clustering analysis based on 7 parameters with high chi-square ranking (total SOD activity, oxidative stress levels, catalase transcripts, SOD1 protein levels, metabolic response to mM concentrations of tert-butyl hydroperoxide, glutathione reductase activity, and Nrf2 transcript levels) provided a perfect cluster segregation between samples from healthy controls and ALS (undSOD1 and mutSOD1), also visualized in the PCA.
Our results show distinct redox signatures in lymphoblasts from mutSOD1, undSOD1 and healthy controls that can be used as therapeutic targets for ALS drug development.
肌萎缩侧索硬化症(ALS)是一种致命且迅速进展的神经退行性疾病,影响运动神经元。这种疾病与氧化应激有关,尤其是在突变超氧化物歧化酶 1(mutSOD1)患者中。然而,由于缺乏疾病模型,对于最常见的散发性 ALS 形式,了解较少。在这里,我们研究了具有 mutSOD1 或未知(undSOD1)突变的 ALS 患者的淋巴母细胞中的氧化应激谱。
从 Coriell 获得 mutSOD1 和 undSOD1 淋巴母细胞,并将其分为 46 岁男性(C1)、46 岁女性(C2)或 26/27 岁男性(C3)队列。进行生长曲线,评估与氧化还原平衡相关的几个参数,包括 SOD 活性和表达、总氧化应激水平、脂质过氧化、氧化应激反应、谷胱甘肽氧化还原循环、过氧化氢酶表达和活性以及 Nrf2 转录物。进行了汇总(所有队列)和配对(队列内)统计分析,随后进行聚类和主成分分析(PCA)。
尽管在不同队列之间发现了淋巴母细胞氧化还原谱之间的高度异质性,但基于 7 个具有高卡方排名的参数(总 SOD 活性、氧化应激水平、过氧化氢酶转录物、SOD1 蛋白水平、代谢对 mM 浓度叔丁基过氧化氢的反应、谷胱甘肽还原酶活性和 Nrf2 转录物水平)的聚类分析,在 PCA 中也可以完美地分离健康对照和 ALS(undSOD1 和 mutSOD1)之间的样本。
我们的结果显示,mutSOD1、undSOD1 和健康对照的淋巴母细胞中存在明显的氧化还原特征,可作为 ALS 药物开发的治疗靶点。